121 related articles for article (PubMed ID: 35078272)
1. Healthcare cost by primary tumour, functioning status and treatment among patients with metastatic neuroendocrine tumours: The LyREMeNET study.
Perrier M; Polazzi S; Lemelin A; Fernandez V; Labonne S; Maucort-Boulch D; Lombard-Bohas C; Duclos A; Walter T
J Neuroendocrinol; 2022 Apr; 34(4):e13092. PubMed ID: 35078272
[TBL] [Abstract][Full Text] [Related]
2. Health care resource use and costs among patients with carcinoid syndrome in France: Analysis of the National Health Insurance Database.
Perrier M; Mouawad C; Gueguen D; Thomé B; Lapeyre-Mestre M; Walter T
Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102177. PubMed ID: 37453678
[TBL] [Abstract][Full Text] [Related]
3. Elderly Patients with Metastatic Neuroendocrine Tumors Are Undertreated and Have Shorter Survival: The LyREMeNET Study.
Lemelin A; Maucort-Boulch D; Castel-Kremer E; Forestier J; Hervieu V; Lorcet M; Boutitie F; Theillaumas A; Robinson P; Duclos A; Lombard-Bohas C; Walter T
Neuroendocrinology; 2020; 110(7-8):653-661. PubMed ID: 31586998
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
[TBL] [Abstract][Full Text] [Related]
5. Peptide receptor radionuclide therapy induced carcinoid crisis: A case report.
Siow Ping L; Azraai BN; Subashini R
Med J Malaysia; 2022 Jan; 77(1):128-131. PubMed ID: 35087014
[TBL] [Abstract][Full Text] [Related]
6. Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database.
Fisher MD; Pulgar S; Kulke MH; Mirakhur B; Miller PJ; Walker MS; Schwartzberg LS
J Gastrointest Cancer; 2019 Dec; 50(4):816-823. PubMed ID: 30121904
[TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
8. Midgut Neuroendocrine Tumors with Liver-only Metastases: Benefit of Primary Tumor Resection.
Gangi A; Manguso N; Gong J; Crystal JS; Paski SC; Hendifar AE; Tuli R
Ann Surg Oncol; 2020 Oct; 27(11):4525-4532. PubMed ID: 32394299
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.
Goncalves I; Burbury K; Michael M; Iravani A; Ravi Kumar AS; Akhurst T; Tiong IS; Blombery P; Hofman MS; Westerman D; Hicks RJ; Kong G
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1902-1910. PubMed ID: 31187162
[TBL] [Abstract][Full Text] [Related]
10. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study.
Custodio A; Jimenez-Fonseca P; Carmona-Bayonas A; Gomez MJ; Del Olmo-García MI; Lorenzo I; Díaz JÁ; Canal N; De la Cruz G; Villabona C
Clin Transl Oncol; 2021 Oct; 23(10):2046-2056. PubMed ID: 34109562
[TBL] [Abstract][Full Text] [Related]
11. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
12. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
[TBL] [Abstract][Full Text] [Related]
13. Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources.
Darbà J; Marsà A
BMC Cancer; 2019 Dec; 19(1):1226. PubMed ID: 31842791
[TBL] [Abstract][Full Text] [Related]
14. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
[TBL] [Abstract][Full Text] [Related]
15. Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions.
Tapia Rico G; Li M; Pavlakis N; Cehic G; Price TJ
Cancer Treat Rev; 2018 May; 66():1-6. PubMed ID: 29602040
[TBL] [Abstract][Full Text] [Related]
16. The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Subramanian J; Fernandes AW; Laliberté F; Pavilack M; DerSarkissian M; Duh MS
Lung Cancer; 2019 Dec; 138():131-138. PubMed ID: 31733614
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
[TBL] [Abstract][Full Text] [Related]
18. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients.
Shen C; Chu Y; Halperin DM; Dasari A; Zhou S; Xu Y; Yao JC; Shih YT
Oncologist; 2017 Dec; 22(12):1451-1462. PubMed ID: 28642335
[TBL] [Abstract][Full Text] [Related]
19. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
